Amarin Plc(NASDAQ) AMRN

Amarin Corporation plc NASDAQ:AMRN helps people lower heart disease risks. Its prescription medicine helps adults reduce high fat levels in the blood. This treatment works with healthy diets to improve long-term heart health.

What Amarin Brings to Pharmacies

• VASCEPA: Prescription omega-3 fatty acid used to reduce very high triglyceride levels in adult patients; known as VAZKEPA in Europe.
• Cardiovascular Risk Reduction: Supplemental therapy for high-risk patients on statins to prevent major heart events like heart attacks or strokes.
• Collaborative Drug Development: Research and marketing of drug products derived from omega-3 acid in partnership with other pharmaceutical firms.

Expanding Across Global Borders

• Entered a long-term license agreement with Recordati in June 2025 to manage sales in 59 European countries.
• Established partnerships with seven commercial companies to reach markets in China, Canada, Australia, and the Middle East.
• Secured a European patent in April 2024 that extends market exclusivity for its main product until 2039.
• Obtained national reimbursement approvals in countries like Spain, Italy, and the Netherlands between 2023 and 2025.

How the Company Stays Competitive

Amarin manages a diverse supply chain with multiple approved manufacturers to prevent any inventory shortages. The company also maintains a strong scientific foundation with its icosapent ethyl treatment recognized in over 70 medical guidelines.

Checking the Financial Pulse

• Total revenue, net was $42.2 million in the three months ended June 30, 2026, down 42% year over year.
• U.S. net product revenue reached $67.9 million during the six months ended June 30, 2026.
• Cash, cash equivalents, and short-term investments totaled $314.9 million as of June 30, 2026.
• Gross margin on product sales was 34% for the six-month period ended June 30, 2026.
• Selling, general, and administrative expenses fell 42% to $43.3 million during the six months ended June 30, 2026.

The Road Ahead

Amarin has transitioned from a direct sales model to a partnership-driven strategy to navigate U.S. generic competition. This shift focuses on international expansion and operational efficiency to maintain its position in the heart health market.